

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA – Upadacitinib for treating moderate to severe
rheumatoid arthritis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process, if so, what are they?

The increased difficulty of assessing outcome measures people with communication difficulties was raised as a potential equality issue after consulting on the scope.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Other appraisals in a similar disease area included recommendations that healthcare professionals should take into account any communication difficulties when using certain outcome measures.

Therefore, the committee should consider the extent to which these difficulties could affect results. Also, for consistency, it should consider recommending that, when using these measures, healthcare professionals make any adjustments they consider appropriate.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A

Approved by Associate Director: Jasdeep Hayre

Date: 26/04/19